Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

被引：106

作者：

Avet-Loiseau, Herve ^{[1
,2
]}

Malard, Florent ^{[2
]}

Campion, Loic ^{[3
]}

Magrangeas, Florence ^{[2
]}

Sebban, Catherine ^{[4
]}

Lioure, Bruno ^{[5
]}

Decaux, Olivier ^{[6
]}

Lamy, Thierry ^{[7
]}

Legros, Laurence ^{[8
]}

Fuzibet, Jean-Gabriel ^{[9
]}

Michallet, Mauricette ^{[10
]}

Corront, Bernadette ^{[11
]}

Lenain, Pascal ^{[12
]}

Hulin, Cyrille ^{[13
]}

Mathiot, Claire ^{[14
]}

Attal, Michel ^{[15
]}

Facon, Thierry ^{[16
]}

Harousseau, Jean-Luc ^{[17
]}

Minvielle, Stephane ^{[2
]}

Moreau, Philippe ^{[18
]}

机构：

[1] Univ Hosp, Hematol Lab, Inst Biol, F-44093 Nantes, France

[2] INSERM, U892, Nantes, France

[3] Ctr Rene Gauducheau, Dept Stat, F-44035 Nantes, France

[4] Ctr Leon Berard, Dept Hematol, F-69373 Lyon, France

[5] Univ Hosp, Dept Hematol, Strasbourg, France

[6] Univ Hosp, Dept Internal Med, Rennes, France

[7] Univ Hosp, Dept Hematol, Rennes, France

[8] Univ Hosp, Dept Hematol, Nice, France

[9] Univ Hosp, Dept Internal Med, Nice, France

[10] Univ Hosp, Dept Hematol, Lyon, France

[11] Univ Hosp, Dept Hematol, Annecy, France

[12] Ctr Francois Baclesse, Dept Hematol, Rouen, France

[13] Univ Hosp, Dept Hematol, Nancy, France

[14] Inst Curie, Hematol Lab, Paris, France

[15] Univ Hosp, Dept Hematol, Toulouse, France

[16] Univ Hosp, Dept Hematol, Lille, France

[17] Ctr Rene Gauducheau, Dept Hematol, F-44035 Nantes, France

[18] Univ Hosp, Dept Hematol, Nantes, France

来源：

BLOOD | 2011年 / 117卷 / 06期

关键词：

STEM-CELL TRANSPLANTATION; C-MAF; MAINTENANCE; THALIDOMIDE; EXPRESSION; SURVIVAL; THERAPY; TRIAL; GENE;

D O I：

10.1182/blood-2010-07-295105

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Many trials in myeloma are stratified on cytogenetic abnormalities. Among them, the most commonly chosen are the t(4;14), the del(17p), and the t(14;16). If data are well established for t(4;14) and del(17p), very few data support the use of t(14;16). To address this issue, we retro-spectively analyzed 1003 patients with newly diagnosed myeloma for this abnormality. We identified 32 patients with the t(14;16). Compared with patients lacking the t(14;16), we did not observe any difference in overall survival (P = .28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma. (Blood. 2011; 117(6): 2009-2011)

引用

页码：2009 / 2011

页数：3

共 50 条

[21] V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
Mutsaers, Pim
Balcioglu, Hayri E.
Kuiper, Rowan
Hammerl, Dora
Wijers, Rebecca
van Duin, Mark
van der Holt, Bronno
Broijl, Annemiek
Gregory, Walter
Zweegman, Sonja
Sonneveld, Pieter
Debets, Reno
CANCERS, 2021, 13 (09)
[22] Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib
Smetana, Jan
Berankova, Kristina
Zaoralova, Romana
Nemec, Pavel
Greslikova, Henrieta
Kupska, Renata
Mikulasova, Aneta
Frohlich, Jan
Sevcikova, Sabina
Zahradova, Lucie
Krejci, Marta
Sandecka, Viera
Almasi, Martina
Kaisarova, Petra
Melicharova, Ham
Adam, Zdenek
Penka, Miroslav
Jarkovsky, Jiri
Jurczyszyn, Arthur
Hajek, Roman
Kuglik, Petr
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (02) : 123 - 130
[23] The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis
Oliveira, Vanessa
Mahajan, Nitin
Bates, Melissa L.
Tripathi, Chakrapani
Kim, Kyusik Q.
Zaher, Hani S.
Maggi, Leonard B., Jr.
Tomasson, Michael H.
FASEB BIOADVANCES, 2019, 1 (07) : 404 - 414
[24] Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray?
Chakraborty, Rajshekhar
Lentzsch, Suzanne
CANCER, 2021, 127 (01) : 31 - 34
[25] CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
Jian, Yuan
Zhang, Zhiyao
Zhou, Huixing
Yang, Guangzhong
Geng, Chuanying
Wang, Huijuan
Gao, Wen
Chen, Wenming
FRONTIERS IN ONCOLOGY, 2022, 12
[26] Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
Hose, Dirk
Reme, Thierry
Hielscher, Thomas
Moreaux, Jerome
Messner, Tobias
Seckinger, Anja
Benner, Axel
Shaughnessy, John D., Jr.
Barlogie, Bart
Zhou, Yiming
Hillengass, Jens
Bertsch, Uta
Neben, Kai
Moehler, Thomas
Rossi, Jean Francois
Jauch, Anna
Klein, Bernard
Goldschmidt, Hartmut
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (01): : 87 - 95
[27] The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population
Yu, Wenjun
Guo, Rui
Qu, Xiaoyan
Qiu, Hairong
Li, Jianyong
Zhang, Run
Chen, Lijuan
ONCOTARGETS AND THERAPY, 2016, 9 : 295 - 301
[28] Highs and lows of t(4;14) in multiple myeloma
Paiva, Bruno
Calasanz, Maria-Jose
BLOOD, 2023, 141 (13) : 1500 - 1502
[29] Natural history of t(11;14) multiple myeloma
Lakshman, A.
Moustafa, M. Alhaj
Rajkumar, S. V.
Dispenzieri, A.
Gertz, M. A.
Buadi, F. K.
Lacy, M. Q.
Dingli, D.
Fonder, A. L.
Hayman, S. R.
Hobbs, M. A.
Gonsalves, W. I.
Hwa, Y. L.
Kapoor, P.
Leung, N.
Go, R. S.
Lin, Y.
Kourelis, T. V.
Lust, J. A.
Russell, S. J.
Zeldenrust, S. R.
Kyle, R. A.
Kumar, S. K.
LEUKEMIA, 2018, 32 (01) : 131 - 138
[30] Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
Mina, Roberto
Joseph, Nisha S.
Gay, Francesca
Kastritis, Efstathios
Petrucci, Maria Teresa
Kaufman, Jonathan L.
Montefusco, Vittorio
Gavriatopoulou, Maria
Patriarca, Francesca
Omede, Paola
Boise, Lawrence H.
Roussou, Maria
Giuliani, Nicola
Oliva, Stefania
Offidani, Massimo
Belotti, Angelo
Jaye, David L.
De Paoli, Lorenzo
Terpos, Evangelos
Lonial, Sagar
Boccadoro, Mario
Nooka, Ajay K.
Dimopoulos, Meletios A.
BLOOD CANCER JOURNAL, 2020, 10 (04)

← 1 2 3 4 5 →